Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l’adulte et l’enfant : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Gauthier, 2017, Chimeric antigen receptor T cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives, Curr Res Transl Med, 65, 93, 10.1016/j.retram.2017.08.003

Grupp, 2018, Beginning the CAR-T cell therapy revolution in the US and EU, Curr Res Transl Med, 66, 62, 10.1016/j.retram.2018.03.004

Quesnel, 2018, CAR-T cells: a John von Neumann legacy?, Curr Res Transl Med, 66, 35, 10.1016/j.retram.2018.04.002

Ghobadi, 2018, Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma, Curr Res Transl Med, 66, 43, 10.1016/j.retram.2018.03.005

Liu, 2018, CRISPR/Cas9 genome editing: fueling the revolution in cancer immunotherapy, Curr Res Transl Med, 66, 39, 10.1016/j.retram.2018.04.003

Lonez, 2018, Celyad's novel CAR-T cell therapy for solid malignancies, Curr Res Transl Med, 66, 53, 10.1016/j.retram.2018.03.001

Prommersberger, 2018, Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia, Curr Res Transl Med, 66, 37, 10.1016/j.retram.2018.03.006

Gauthier, 2018, Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy, Curr Res Transl Med, 66, 50, 10.1016/j.retram.2018.03.003

Chabannon, 2018, Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations, Curr Res Transl Med, 66, 59, 10.1016/j.retram.2018.03.002

Yakoub-Agha, 2018, Clinical units to set up chimeric antigen receptor T cell therapy (CAR-T cells): based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), Curr Res Transl Med, 66, 57, 10.1016/j.retram.2018.04.001

Yakoub-Agha, 2017, [Prerequisite for hematopoietic cellular therapy programs to set up chimeric antigen receptor T cell therapy (CAR-T cells): guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)], Bull Cancer, 104, S43, 10.1016/j.bulcan.2017.10.017

Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, Blood, 121, 5154, 10.1182/blood-2013-02-485623

Topp, 2015, Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study, Lancet Oncol, 16, e158

Raj, 2018, Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome, Biol Blood Marrow Transplant, 24, 1664, 10.1016/j.bbmt.2018.04.010

Ureshino, 2017, Tocilizumab for severe cytokine release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B cell lymphoma, Hematol Oncol, 36, 324, 10.1002/hon.2481

Abboud, 2016, Severe cytokine release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated, Biol Blood Marrow Transplant, 22, 1851, 10.1016/j.bbmt.2016.06.010

Frey, 2017, Cytokine release syndrome: who is at risk and how to treat, Best Pract Res Clin Haematol, 30, 336, 10.1016/j.beha.2017.09.002

Neelapu, 2017, Chimeric antigen receptor T cell therapy – assessment and management of toxicities, Nat Rev Clin Oncol, 15, 47, 10.1038/nrclinonc.2017.148

Norelli, 2018, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine release syndrome and neurotoxicity due to CAR-T cells, Nat Med, 24, 739, 10.1038/s41591-018-0036-4

Giavridis, 2018, CAR-T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade, Nat Med, 24, 731, 10.1038/s41591-018-0041-7

Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222

Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919

Davila, 2014, Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med, 6, 224ra25, 10.1126/scitranslmed.3008226

Maude, 2015, CD19-targeted chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Blood, 125, 4017, 10.1182/blood-2014-12-580068

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet (London, England), 385, 517, 10.1016/S0140-6736(14)61403-3

Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309

Frey, 2016, Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia, Hematol Am Soc Hematol Educ Program, 2016, 567, 10.1182/asheducation-2016.1.567

Frey, 2016, Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL), ASCO Abstract

Turtle, 2015, Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes, ASH Abstract

Tipton, 2016, [How we harmonize HSCT clinical practices among the SFGM-TC centers], Bull Cancer, 103, S193, 10.1016/j.bulcan.2016.09.006

Park, 2016, CD19-targeted CAR-T cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date, Blood, 127, 3312, 10.1182/blood-2016-02-629063

Santomasso, 2018, Clinical and biological correlates of neurotoxicity associated with CAR-T cell therapy in patients with B cell acute lymphoblastic leukemia, Cancer Discov, 8, 958, 10.1158/2159-8290.CD-17-1319

Hill, 2017, Infectious complications of CD19-targeted chimeric antigen receptor-modified T cell immunotherapy, Blood, 131, 121, 10.1182/blood-2017-07-793760

Lee, 2014, Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 188, 10.1182/blood-2014-05-552729

Moreau, 2016, [Transfer of allogeneic stem cell transplant recipients to the intensive care unit: guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)], Bull Cancer, 103, S220, 10.1016/j.bulcan.2016.09.008

Hu, 2017, Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia, Clin Cancer Res, 23, 3297, 10.1158/1078-0432.CCR-16-1799

Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR-T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208

Singer, 2016, The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287

Davis, 2017, American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock, Crit Care Med, 45, 1061, 10.1097/CCM.0000000000002425

Mahadeo, 2018, Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, Nat Rev Clin Oncol

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Cancer Discov, 6, 664, 10.1158/2159-8290.CD-16-0040

Liu, 2018, Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T cell therapy, J Immunother, 41, 406, 10.1097/CJI.0000000000000243

Titov, 2018, The biological basis and clinical symptoms of CAR-T therapy-associated toxicites, Cell Death Dis, 9, 897, 10.1038/s41419-018-0918-x

Hay, 2017, Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B cell malignancies, Drugs, 77, 237, 10.1007/s40265-017-0690-8

Fitzgerald, 2017, Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia, Crit Care Med, 45, e124, 10.1097/CCM.0000000000002053

Neelapu, 2017, Axicabtagene Ciloleucel CAR-T cell therapy in refractory large B cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447

FDA, 2018

Maude, 2018, Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866